These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 23609423)
1. Improving health with partnerships between academia and industry. Desmond-Hellmann S JAMA Intern Med; 2013 Jun; 173(12):1051-2. PubMed ID: 23609423 [No Abstract] [Full Text] [Related]
2. Biomarker qualification via public-private partnerships. Eck SL; Paul SM Clin Pharmacol Ther; 2010 Jan; 87(1):21-3. PubMed ID: 20019697 [TBL] [Abstract][Full Text] [Related]
3. Conflicts of interest with the health industry. Dubois MY Pain Med; 2006; 7(5):463-5. PubMed ID: 17014609 [No Abstract] [Full Text] [Related]
4. A principled partnership between academic medicine and industry. Kirch DG Medscape J Med; 2008; 10(8):198. PubMed ID: 18924650 [No Abstract] [Full Text] [Related]
5. True, false, whatever. Schultz S US News World Rep; 2001 Sep; 131(10):72-3. PubMed ID: 11573469 [No Abstract] [Full Text] [Related]
6. Out in the open. Nat Biotechnol; 2005 Feb; 23(2):153. PubMed ID: 15696130 [No Abstract] [Full Text] [Related]
8. Academia-industry partnerships: are we ready for new models of partnership?: the point of view of the EORTC, an academic clinical cancer research organisation. Lacombe D; Burock S; Meunier F Eur J Cancer; 2013 Jan; 49(1):1-7. PubMed ID: 23079476 [No Abstract] [Full Text] [Related]
9. Guidelines and policies for medical writers in the biotech industry: an update on the controversy. Foote M Biotechnol Annu Rev; 2004; 10():259-64. PubMed ID: 15504710 [TBL] [Abstract][Full Text] [Related]
10. How academic labs can approach the drug discovery process as a way to synergize with big pharma. Loregian A; Palù G Trends Microbiol; 2013 Jun; 21(6):261-4. PubMed ID: 23731493 [TBL] [Abstract][Full Text] [Related]
11. Trial and error. Printz C Cancer; 2013 Feb; 119(3):471-2. PubMed ID: 23341304 [No Abstract] [Full Text] [Related]
12. Changing roles for academia and industry in genetics and gene therapy. Friedmann T Mol Ther; 2000 Jan; 1(1):9-11. PubMed ID: 10933906 [No Abstract] [Full Text] [Related]
13. Transparency battle resurfaces as EU trial revamp wraps up. Holmes D Nat Med; 2013 Jul; 19(7):797. PubMed ID: 23836204 [No Abstract] [Full Text] [Related]
14. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Melese T; Lin SM; Chang JL; Cohen NH Nat Med; 2009 May; 15(5):502-7. PubMed ID: 19424212 [No Abstract] [Full Text] [Related]
15. Making translation work. Williams RS; Desmond-Hellmann S Science; 2011 Jun; 332(6036):1359. PubMed ID: 21680815 [No Abstract] [Full Text] [Related]
16. Enhancing ties between academia and industry to improve health. Johnston SC; Hauser SL; Desmond-Hellmann S Nat Med; 2011 Apr; 17(4):434-6. PubMed ID: 21475239 [TBL] [Abstract][Full Text] [Related]
17. Guinea-pigging: healthy human subjects for drug safety trials are in demand. But is it a living? Elliott C New Yorker; 2008 Jan; ():36-41. PubMed ID: 18265451 [No Abstract] [Full Text] [Related]
18. Forget sponsorship and free trips--welcome to Pharmacare. Moynihan R BMJ; 2011 Jan; 344():d8316. PubMed ID: 22218100 [No Abstract] [Full Text] [Related]
20. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A proposal to increase participation in Alzheimer's disease clinical trials. Ryan JM; Schneider G; Jacobsen JS Alzheimers Dement; 2009 Mar; 5(2):140-2. PubMed ID: 19328445 [No Abstract] [Full Text] [Related] [Next] [New Search]